SCHEMBL18100340

SCHEMBL18100340

CO/C(=N\c1ccc(Oc2ccc(-c3ccc(Oc4ccc(/N=C(\OC)c5ccccc5)cc4)cc3)cc2)cc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 2/20 0.43
▸ NOS1 P29475 2/20 0.43
▸ NOS2 P35228 2/20 0.43
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ ACACB O00763 2/20 0.41
▸ ACACA Q13085 2/20 0.41
▸ LTA4H P09960 1/20 0.40
▸ FURIN P09958 1/20 0.39
▸ ERN1 O75460 1/20 0.39
▸ PGR P06401 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ BCL2L1 Q07817 1/20 0.38
▸ MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663895 0.90 RAB9A (0.40) NOS3NOS1SMN1; SMN2MEN1POLB
SCHEMBL18100418 0.86 TSHR (0.45) NOS3NOS1HPGDSMN1; SMN2MEN1
SCHEMBL18100335 0.85 NOS3 (0.40) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL8815637 0.85 NOS3 (0.52) NOS3LTA4HHPGDSMN1; SMN2MEN1
SCHEMBL18100300 0.84 MAPT (0.44) NOS3NOS1SMN1; SMN2MEN1KMT2A
SCHEMBL5178578 0.82 KMT2A (0.48) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL18100417 0.82 KMT2A (0.48) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL18100410 0.82 NOS3 (0.37) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL18100353 0.81 PDK1 (0.38) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL15191710 0.80 MAPT (0.56) NOS3NOS1HPGDSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160280851-A1 IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE FUJIFILM CORPORATION (JP) 2016-09-29 — — US disclosed
US-20160280851-A1 IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE FUJIFILM CORPORATION (JP) 2016-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280851-A1 IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE BRS3, RAD1, RAD51 NOS3 2933/4885NOS1 3561/4885NOS2 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback